Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229437 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 343
- Enrollment target
NCT00229437 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 343 participants.
The verdict
NCT00229437, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 343 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.
Interventions
- DRUG Placebo
- DRUG TAK-128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229437
The ClinicalTrials.gov registry entry for NCT00229437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00229437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229437 about?
NCT00229437 is a clinical study titled "Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy". The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.
What is the current status of trial NCT00229437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 343 participants. The study started on 2005-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00229437?
The interventions under investigation include: Placebo (DRUG), TAK-128 (DRUG).
Who is sponsoring clinical trial NCT00229437?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.